AstraZeneca stock falls 1.35 percent as cancer trial expands

Published on 10/04/2026 at 13:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock posted Q2 2026 revenue of USD 15.38 billion, up 6.4 percent year over year. Quarterly EPS reached USD 2.63 against USD 2.50 consensus.

Makroaufnahme bunter Tabletten und Kapseln mit glänzenden Wassertropfen — AstraZeneca plc (ISIN GB0009895292) entwickelt und produziert verschreibungspflichtige Tabletten, Kapseln und weitere Arzneiformen, Illustration mit AI erstellt.

AstraZeneca stock (ISIN GB0009895292) fell 1.35 percent to GBp 11,870.0 on the London Stock Exchange on October 2, 2026. The move followed a new cancer-development collaboration with Daiichi Sankyo and Summit Therapeutics, announced by AstraZeneca on October 2, 2026.

Datroway gains a new trial path

The partners plan to evaluate AstraZeneca and Daiichi Sankyo's Datroway with Summit's ivonescimab across lung and breast cancer settings. The program is intended to begin with a Phase III study in first-line triple-negative breast cancer, while each company contributes its medicine and shares trial costs.

The commercial structure is also defined: AstraZeneca, Daiichi Sankyo and Summit will retain development and commercial rights to their respective medicines. Reuters reported on October 2, 2026, that the collaboration covers multiple tumor types, including lung and breast cancers.

Q2 revenue rose 6.4 percent

The latest reported operating picture is from Q2 2026. According to MarketBeat, revenue increased 6.4 percent year over year to USD 15.38 billion, while EPS came in at USD 2.63 against a USD 2.50 consensus estimate. Revenue therefore missed the USD 15.44 billion estimate despite the earnings-per-share beat.

Analysts see GBP 150 target

MarketBeat reported on October 4, 2026, that seven analysts had a Moderate Buy consensus and an average 12-month price target of GBP 150. Berenberg cut its target from GBP 160 to GBP 150 on September 15, 2026, while Deutsche Bank reaffirmed a Hold rating with a GBP 117 target on September 29, 2026.

Stock remains below yearly high

AstraZeneca stock closed at GBp 11,870.0 on October 2, 2026, with a session range of GBp 11,790.0 to GBp 12,094.0 and volume of 1.62 million shares. The 52-week range was GBp 11,404.0 to GBp 15,730.0, leaving the stock 24.5 percent below its yearly high.